Gensight Biologics SA (SIGHT)

Paris
Currency in EUR
0.29
-0.02(-6.55%)
Closed
SIGHT Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
Fair Value
Day's Range
0.290.31
52 wk Range
0.230.60
Key Statistics
Edit
Prev. Close
0.29
Open
0.3
Day's Range
0.29-0.31
52 wk Range
0.23-0.6
Volume
297.61K
Average Volume (3m)
295.03K
1-Year Change
-24.97%
Book Value / Share
-0.24
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SIGHT Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
0.36
Upside
+24.14%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Gensight Biologics Company Profile

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. It has license agreements with Sorbonne Université, CNRS, Inserm and SATT Lutech; Inserm Transfert S.A, Genethon, and Harvard; Massachusetts Institute of Technology; Novartis Pharma AG; Sorbonne University, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale and Satt Lutech; Association Française contre les Myopathies, Inserm Transfert S.A; and non-exclusive license agreement with Adverum Biotechnologies. The company was incorporated in 2012 and is headquartered in Paris, France.

Compare SIGHT to Peers and Sector

Metrics to compare
SIGHT
Peers
Sector
Relationship
P/E Ratio
−1.9x−2.7x−0.6x
PEG Ratio
−0.03−0.110.00
Price/Book
−1.6x1.6x2.6x
Price / LTM Sales
19.5x5.7x3.1x
Upside (Analyst Target)
24.1%160.5%52.8%
Fair Value Upside
Unlock4.6%8.4%Unlock

Analyst Ratings

0 Buy
1 Hold
1 Sell
Ratings:
2 analysts
Overall Consensus
Sell

Analysts 12-Month Price Target:

Average 0.36
(+24.14% Upside)

Earnings

Latest Release
Oct 24, 2024
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

10.78
CRIP
+1.51%
21.25
CBLP
+0.47%
37.50
EQSE
+0.94%
1.150
ALBIO
-1.72%

FAQ

What Is the Gensight Biologics (SIGHT) Stock Price Today?

The Gensight Biologics stock price today is 0.29

What Stock Exchange Does Gensight Biologics Trade On?

Gensight Biologics is listed and trades on the Paris stock exchange.

What Is the Stock Symbol for Gensight Biologics?

The stock symbol for Gensight Biologics is "SIGHT."

What Is the Gensight Biologics Market Cap?

As of today, Gensight Biologics market cap is 36.12M.

What is Gensight Biologics Earnings Per Share?

The Gensight Biologics EPS is -0.302.

What Is the Next Gensight Biologics Earnings Date?

Gensight Biologics will release its next earnings report on 21 Mar 2025.

From a Technical Analysis Perspective, Is SIGHT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.